Leptin, a 16-kDa protein secreted from white adipocytes, has been implicated in the regulation of food intake, energy expenditure, and whole-body energy balance in rodents and humans. The gene encoding leptin was identified by positional cloning and is the mutation leading to the profound obese phenotype of the ob/ob mouse. Exogenous administration of leptin to ob/ob mice leads to a significant improvement in reproductive and endocrine status as well as reduced food intake and weight loss. The expression and secretion of leptin is highly correlated with body fat mass and adipocyte size. Cortisol and insulin are potent stimulators of leptin expression, and expression is attenuated by b-adrenergic agonists, cAMP, and thiazolidinediones. The role of other hormones and growth factors in the regulation of leptin expression and secretion is emerging. Leptin circulates specifically bound to proteins in serum, which may regulate its half-life and biological activity. Isoforms of the leptin receptor, members of the interleukin-6 cytokine family of receptors, are found in multiple tissues, including the brain. Many of leptin's effects on food intake and energy expenditure are thought to be mediated centrally via neurotransmitters such as neuropeptide Y. Multiple peripheral effects of leptin have also been recently described, including the regulation of insulin secretion by pancreatic b cells and regulation of insulin action and energy metabolism in adipocytes and skeletal muscle. Leptin is thought to be a metabolic signal that regulates nutritional status effects on reproductive function. Leptin also plays a major role in hematopoeisis and in the anorexia accompanying an acute cytokine challenge. The profound effects of leptin on regulating body energy balance make it a prime candidate for drug therapies for humans and animals.
Introduction
Obesity is a major health issue in much of the human population. In the United States, it is estimated that over 30% of the population is overweight by at least 20%, and this proportion is increasing. A conservative estimate over 10 yr ago of the total economic costs of obesity in the United States was $39.3 billion, considering all of the associated diseases; more recent estimates are much higher (Colditz, 1992) . It is also estimated that at least $30 billion is spent to treat obesity in the United States annually (Gura, 1997) . Most attempts to treat obesity to date, except for the several types of surgical removal of the tissue, have failed to result in a sustained reduction of obesity. An example of the sensitivity of the physiology of weight maintenance is that the average woman may gain 11 kg between the ages of 25 and 65, and this is the result of only 350 mg of excess daily food on the average. This is in the face of more than 18 t of food intake over the 40 yr, or an error of less than .03%.
Obesity per se is not a major concern for animal agriculture. However, altering body composition by repartitioning of nutrients to favor lean protein accretion and improve productive efficiency are major goals for animal scientists. Furthermore, regulation of feed intake and whole-body energy balance in livestock species is important for optimizing animal growth, reproduction, lactation, and overall health and well-being. Thus, understanding the basic mechanisms that regulate adiposity, feed intake, and energy metabolism in livestock may lead to new technologies that will further enhance animal performance and health. 
History and Features of ob/ob Mice
Research of human obesity and its treatment has included extensive use of animal models. One of the early models identified is the ob/ob mouse, discovered in 1950 (Ingalls et al., 1950) . Animal caretakers at the Jackson Laboratories discovered this mouse on the C57BL/6J background. Over the years, these mice have been the subject of many Science and Nature "breakthrough" publications.
The ob/ob mice have a recessive genetic obesity that results in sterile adult mice with over 50% fat. A close relative, db/db, was later discovered; these mice arose on the C57BL/KSJ background. These mice were similarly obese but also were hyperglycemic (Hummel et al., 1966) . Coleman, of the Jackson Laboratories, reported seminal studies using parabiosis (crosscirculation) of these mice (Coleman, 1973) . Research with parabiotic pairs of the ob/ob and db/db mice showed a decrease in food intake and body weight in the ob/ob pair-mates and a retention of increased food intake and weight in their db/db pair-mates. Coleman concluded that ob/ob mice fail to make a circulating factor from adipose tissue but their brains can respond to it and reduce food intake, whereas db/db mice make the circulating factor in their adipose tissue but their brains cannot respond to it. It was not until 1995 that studies were possible to verify these hypotheses.
Discovery of the Ob Gene
Even though many observations of the metabolism and physiology of the ob/ob mice were reported, the real genetic defect was impossible to elucidate until the powerful tools of biotechnology were available. A team led by Jeffrey Friedman at Rockefeller University published the specific gene defect of ob/ob mice in December 1994 after an 8-yr search (Zhang et al., 1994) . Three papers in 1995 clearly showed that the ob protein, leptin, eliminated the obesity of the ob/ob mice Pelleymounter et al., 1995; Rentsch et al., 1995) , and these have led to an estimated 250 publications in 1996 and nearly another 250 publications in the first half of 1997 on leptin biology and chemistry. Also associated with this discovery has been a huge influx of industrial investment into research and applications for novel treatments of obesity.
The ob/ob mouse produces no leptin, due to the gene mutation. The genetic basis of other obesities in rodents have now been reported and are summarized in Table 1 . It is interesting that none of these has led to an explanation of any prevalent form of human obesity. In 1997, a very infrequent form of hunger and obesity in humans was reported in two patients; it was confirmed to be the result of a lack of leptin production by their adipocytes (Montague et al., 1997) . It has been proposed that a composite of genes is likely to be responsible for most human obesities, and therefore much more research will be required to make major strides in the understanding of this human condition.
The leptin gene has been cloned in pigs (Bidwell et al., 1997) , and the cloning of leptin genes in other livestock species will likely be reported in the near future. Due to the lack of published data in farm animals, the importance of leptin as a genetic marker for animal growth, reproductive, and lactational performance remains to be determined.
Discovery and Function of Leptin Receptors
Tartaglia and coworkers (Tartaglia et al., 1995) reported the cloning of the leptin receptor in December 1995. A high-affinity leptin receptor was cloned from mouse choroid plexus (Tartaglia et al., 1995) and was genetically mapped to the same interval of mouse chromosome 4 that contains the db locus (Tartaglia et al., 1995) . In the db/db mouse, the mRNA for the long form of the receptor is abnormal and yields a receptor with a truncated intracellular domain that is unable to appropriately signal (Chen et al., 1996b; Chua et al., 1996; Ghilardi et al., 1996; Lee et al., 1996; Vaisse et al., 1996) , thus confirming the prediction made by Coleman based on parabiosis studies.
Several splice variants of the single gene exist, including the "long" form of the receptor that contains a 302 amino acid intracellular domain. The long form of the receptor is expressed in various regions of the brain and is thought to be responsible for the central actions of leptin (Tartaglia et al., 1995; Glaum et al., 1996; Mercer et al., 1996b; Elmquist et al., 1997) . The helical structure of leptin implied that the leptin receptor would be similar in structure and function to the helical cytokine receptors. This expectation was confirmed when the receptor was determined to be similar to the gp130 signal transduction arm of class I cytokine receptor family members, interleukin ( IL)-6, granulocyte colony stimulating factor ( G-CSF) , and leukemia inhibitory factor ( LIF; Tartaglia et al., 1995) . The extracellular domain of the long ( OB-RL) and short ( OB-RS) forms includes two cytokine domains, each containing a single copy of the characteristic Trp-Ser-X-Trp-Ser motif and a fibronectin type III domain (White and Tartaglia, 1996) .
The similarity of the leptin receptor to the class I cytokine receptor family has implications for signal transduction mechanisms. Class I cytokine receptor members typically lack intrinsic tyrosine kinase activity and are activated by formation of homo-or heterodimers (Watowich et al., 1996) . Leptin receptors have been reported to form homodimers (Nakashima et al., 1997; White et al., 1997) . Briefly, following ligand-receptor binding and receptor aggregation, phosphorylation events ultimately result in activation of Janus kinases ( JAK) . The JAK then phosphorylate specific receptor tyrosine residues that provide docking sites for members of the signal transducers and activators of transcription ( STAT) family. Phosphorylation of these transcription factors by JAK is followed by their dimerization and translocation to the nucleus for regulatory purposes.
Leptin signaling via the JAK-STAT pathway has been reasonably well documented and is associated largely with the OB-RL isoform. In mice, administration of recombinant leptin causes activation of STAT3 in the hypothalamus of wild-type and ob/ob mice (Vaisse et al., 1996) . The STAT3 and STAT5 are activated in COS cells following ligand binding to OB-RL, but results for STAT1 and STAT6 were equivocal (Ghilardi and Skoda, 1997) . However, Rosenblum et al. (1996) reported formation of STAT1, STAT3, and mixed STAT1:STAT3 dimers in cells transfected with OB-RL and treated with leptin. Tyrosine phosphorylation of STAT1 has also been demonstrated in a human renal adenocarcinoma cell line after treatment with leptin (Takahashi et al., 1996) .
Signal transduction by members of the class I cytokine receptor family is not limited to the JAK-STAT system. Some of these receptors are linked to mitogen-activated protein kinase ( MAPK) or phosphotidyl inositol-3 ( PI-3) kinase pathways (Watowich et al., 1996) . It is yet to be determined whether ligand binding to one or more of the leptin receptor isoforms activates signaling systems other than the JAK-STAT pathway and which biochemical processes are regulated through them.
Even though leptin is exclusively produced and secreted by adipocytes (Kline et al., 1997) and placenta (Gong et al., 1996) , leptin receptors are found in most tissues. The long form is especially prevalent in the hypothalamus (arcuate, lateral, ventromedial, and dorsomedial nuclei) and not present in most other tissues (Mercer et al., 1996b; Schwartz et al., 1996c) , and the short forms are more ubiquitously expressed. It has been proposed that some of the receptor forms are involved in the transport of leptin in blood and its crossing of the blood-brain barrier (Devos et al., 1996) .
Roles of Leptin in Energy Balance Regulation
In the fed, steady-state (zero energy balance), leptin expression and secretion reflect body fat mass in rodents and humans (Frederich et al., 1995a; Maffei et al., 1995; Considine et al., 1996) and are highly correlated with adipocyte size in lean and obese mice (Houseknecht et al., 1996a,b) . This correlation with fat mass is drastically altered, however, with changes in energy balance. Food deprivation (12 to 48 h ) results in a rapid and drastic fall in leptin gene expression (Cusin et al., 1995; Frederich et al., 1995b; Trayhurn et al., 1995; Kolaczynski et al., 1996a) . However, more subtle changes in energy balance have profound effects on leptin expression as well. As little as a 10% reduction in body weight in obese human subjects results in a 53% reduction in serum leptin , and a 10% increase in body weight causes a 300% increase in serum leptin . Thus, leptin not only functions as an "adipostat" to signal the status of body energy stores to the brain (and perhaps other tissues), but also functions as a sensor of energy balance.
Leptin treatment of animals has been shown to cause a dose-dependent decrease in food intake, loss of body weight, loss of fat depots, and an increase in energy metabolism (Pelleymounter et al., 1995; Levin et al., 1996) . Leptin treatments can be used to eliminate all visible fat in rodents (Chen et al., 1996a) . The body weight and fat losses are unusual following leptin treatment in that the loss of body weight and fat depots are not repleted for several weeks after the termination of the leptin treatment (Chen et al., 1996a; Azain et al., 1997) . Therefore, leptin not only causes reduced food intake, but the potential body weight losses are enhanced due to an increased metabolic rate. This is in contrast to the reduced metabolic rate associated with limited feeding. These effects are observed independently of mode of administration (central vs systemic), although higher doses are required with systemic treatment .
Leptin is known to act centrally to inhibit the effects of neuropeptide Y ( NPY) , apparently by inhibiting its synthesis in the arcuate nucleus of the hypothalamus (Cusin et al., 1996; Erickson et al., 1996b ). There are likely many unknown components of the leptin axis to be discovered to explain its many functions, but it is likely that some of the actions are mediated by the beta-adrenergic enervation of adipose tissue (Collins et al., 1996) and by the uncoupling proteins I and II (Zhou et al., 1997) .
Endocrine Regulation of Leptin Gene Expression and Secretion
Coordinated alterations in leptin gene expression with changing metabolic status suggest hormonal or metabolite control of leptin expression. A prime candidate for such regulation is insulin. Insulin plays a chronic (hours) role in the regulation of leptin levels. Hyperinsulinemia increases leptin levels following 3 to 5 h in rodents and humans (Cusin et al., 1995; Saladin et al., 1995; Utriainen et al., 1996; Vidal et al., 1996) , and in vitro exposure of rat adipocytes to insulin (12 to 48 h ) increased leptin mRNA levels (Slieker et al., 1996) . Leptin concentrations in blood are diurnally regulated in rodents and humans , with levels peaking at night. In rodents, the peak coincides with the initiation of eating behavior, and the elevation is inhibited by fasting (Frederich et al., 1995b; MacDougald et al., 1995; Saladin et al., 1995) and can be reinstated following a meal or a single injection of insulin . In humans, the nocturnal rise in leptin levels does not coincide with feeding , suggesting differential regulation in these two species. We (Houseknecht et al., 1996a) and others (Slieker et al., 1996) have observed no acute (minutes) regulation of leptin secretion by insulin and have found no intracellular storage pool for leptin that could be rapidly mobilized in response to secretagogues such as insulin (Houseknecht et al., 1996a) . It should be noted, however, that leptin concentrations in human plasma are pulsatile in nature (Licinio et al., 1997) , suggesting some yet to be discovered control of leptin secretion and(or) clearance.
Glucocorticoids are potent regulators of leptin expression. The in vivo administration and in vitro incubation of adipocytes (Slieker et al., 1996; Wabitsch et al., 1996) with various glucocorticoids causes an up-regulation of leptin expression. Recent evidence indicates that leptin and cortisol interact in a negative feedback loop; leptin directly inhibits cortisol synthesis by adrenal cells (Bornstein et al., 1997) .
Leptin expression and secretion by adipocytes are down-regulated by adrenergic stimulation, as indicated in studies using b 3 -adrenergic agonists, cold exposure, or dbcAMP (Gettys et al., 1996; Mantzoros et al., 1996) ; Slieker et al., 1996; Trayhurn et al., 1996) . Leptin has been reported to regulate growth hormone secretion (Carro et al., 1997) ; however, chronic incubation of isolated adipocytes with either growth hormone or IGF-I had no effect on leptin expression and secretion .
The Leptin Promoter: C/EBPα, PPARγ, and Leptin Expression
Initial studies of the leptin promoter have revealed functional binding sites for C/EBPa (CCAAT/enhancer binding protein a) in the region −58 to −42 relative to the transcriptional start site (He et al., 1995; MacDougald et al., 1995; Hwang et al., 1996) . The C/EBPa is expressed in multiple cell types, functions as a transcriptional activator of certain adipocyte genes (Christy et al., 1989; Herrera et al., 1989) , and plays a role in terminal adipocyte differentiation (Umek et al., 1991; Freytag and Geddes, 1992) .
Transcriptional regulation of the leptin gene also seems to be controlled by PPARg. The PPARg1 and 2 are members of the family of orphan nuclear receptors that function as trans-activators of fat-specific genes such as aP2, and thus are dominant activators of fat cell differentiation (Tontonoz et al., 1994; Schoonjans et al., 1996a; Schoonjans et al., 1996b) . Thiazolidinediones ( TZD) , pharmacological ligands for the PPARg (Lehmann et al., 1995; Saltiel and Olefsky, 1996) , act to down-regulate leptin mRNA abundance in adipocytes. These data are consistent for a role of PPARg in regulating the leptin promoter (Kallen and Lazar, 1996; Nolan et al., 1996; Zhang et al., 1996) . Hollenberg et al. (1997) recently reported the presence of a canonical DR+1 PPARg binding site located between −3,951 and −3,939 of the mouse 5′-flanking sequence of the leptin gene. Furthermore, these authors report that PPARg2 mediates downregulation of the leptin promoter by inhibiting C/EBP a-mediated transactivation (Hollenberg et al., 1997) .
Mechanisms of Leptin Action: Central vs Peripheral Effects
The lipostatic theory of body weight maintenance, which was developed from parabiosis data (Kennedy, 1953; Hervey, 1958; Hausberger, 1959; Coleman and Hummel, 1969) , proposed a fat-secreted "factor" that reports the status of body energy stores to the brain and thus regulates feeding behavior and body fat mass. Studies examining the effects of exogenous leptin administration to ob/ob mice have led to the development of a deceivingly simple model of leptininitiated energy balance regulation that is reminiscent of the lipostatic theory ( Figure 1 ).
Leptin is synthesized and secreted from white adipocytes into blood and is transported into the brain via a saturable system (Banks et al., 1996) , where it acts to cause the release or inhibition of factors that ultimately result in a reduction in food intake, an Figure 1 . Schematic illustration of leptin secretion and action. Leptin is secreted from white adipocytes into the circulation. Leptin travels to the brain, where it acts to cause the stimulation or inhibition of release of neurotransmitters such as neuropeptide Y (NPY), which act to inhibit food intake and stimulate thermogenesis and physical activity in rodents. Such functions result in a reduction in adipose mass or the stimulation of some other endocrine or auto/paracrine signal that inhibits leptin synthesis and secretion by adipocytes. Leptin may also directly affect the metabolism and function of peripheral tissues such as liver and skeletal muscle as well as adipocytes. (+), stimulation; (−) inhibit; (+/−) stimulate and(or) inhibit; ↑, increase; ↓, decrease. increase in energy expenditure (due at least in part by brown adipose tissue thermogenesis in rodents), and increased physical activity. Additionally, leptin (and perhaps other factors) acts in a negative feedback loop to inhibit further expression of the leptin gene.
Leptin treatment of ob/ob mice causes a rapid reduction in food intake, increased thermogenesis, increased physical activity, and improved glycemia and insulinemia, which occur prior to weight loss Halaas et al., 1995; Pelleymounter et al., 1995; Stephens et al., 1995; Weigle et al., 1995; Schwartz et al., 1996a) .
Many of leptin's effects on the control of food intake and energy expenditure are thought to be mediated centrally. Intense investigation is underway to delineate the targets of leptin action in the brain as well as their downstream effectors. Neuropeptide Y has emerged as a major target of leptin action. The NPY is a potent stimulator of food intake and inhibitor of brown fat thermogenesis (Billington et al., 1991) and increases plasma insulin and corticosteroid levels (Billington et al., 1991; Dryden and Williams, 1996) . The expression of NYP in the hypothalamus is increased in many obese rodent models (including ob/ ob) and with fasting in rats (Marks et al., 1992; Wilding et al., 1993) . Leptin treatment lowers NPY levels in ob/ob mice (Stephens et al., 1995; Schwartz et al., 1996a) , and this occurs before any change in body weight. Additionally, leptin treatment directly suppressed NPY release from perfused rat hypothalami from normal animals (Stephens et al., 1995) . The central role of NPY in leptin action is emphasized by studies in which NPY was knocked out in ob/ob mice (Erickson et al., 1996b) . Absence of NPY attenuated, but did not completely normalize, all aspects of the obesity phenotype in ob/ob mice. These data indicate that NPY is not the only neuroendocrine target of leptin, a fact further supported by data showing that normal mice lacking NPY control their food intake and body weight normally and have a normal response to leptin (Erickson et al., 1996a) .
Mechanisms of Leptin Action: Peripheral Effects
Although significant evidence exists suggesting that leptin effects are mediated centrally via neuropeptides such as NPY, there is mounting evidence that leptin may act peripherally as well (Figure 2 ). Leptin receptors are found outside the central nervous system (Tartaglia et al., 1995) ; however, in many tissues the short form of the receptor predominates (Tartaglia et al., 1995) , and it is not yet clear how effectively the truncated forms of the leptin receptor signal. Leptin has been implicated in causing peripheral insulin resistance by attenuating insulin action (and perhaps insulin signaling) in various insulin-responsive cell types. Exposure of HepG2 cells (Cohen et al., 1996) or rat1 fibroblasts (Kroder et al., 1996) to physiological concentrations of leptin in vitro for minutes, hours, or days results in attenuation of insulin-stimulated phosphorylation of IRS-1 (Cohen et al. 1996; Kroder et al., 1996) and, surprisingly, increased PI3 kinase activity (Cohen et al., 1996) . In contrast, glucose uptake and glycogen synthesis were increased with leptin exposure of the C2/C12 muscle cell-line; PI3-kinase was implicated in the leptin effects (Berti et al., 1997) . A potentially troubling caveat of studies utilizing cultured cells is that the leptin receptor subtypes present in these cell models may not represent those found in primary liver, muscle, or adipose cells. Recently, an elegant study using primary rat adipocytes (Muller et al., 1997) revealed, for the first time in primary insulin-responsive cells, an attenuation of insulin-stimulated glucose metabolism with in vitro exposure to leptin. Additionally, leptin was recently reported to alter lipid partitioning, but not insulin-stimulated glucose metabolism, in isolated mouse skeletal muscle (Muoio et al., 1997) .
Leptin may also elicit its effects on peripheral insulin resistance by affecting insulin secretion. Leptin receptors have been found on pancreatic b-cells (Kieffer et al., 1996) , and leptin has been reported to directly inhibit b-cell secretion of insulin by altering ion channel function (Emilsson et al., 1997; Kieffer et al., 1997) .
A newly described peripheral action of leptin is to regulate the secretion of cortisol, a powerful stimulator of leptin expression. At concentrations in the range found in obese humans (100 ng/mL), leptin reduced cortisol secretion 52% in isolated adrenocortical cells (Bornstein et al., 1997) .
Leptin Resistance
The discovery that mutations in the leptin and leptin receptor genes caused severe obesity in rodents led to the hypothesis that a similar phenomenon was true for humans. In fact, with the exception of the ob/ ob mouse and two children from one family of Pakistani origin (Montague et al., 1997) , all models of rodent and human obesity studied are characterized not by leptin deficiency, but by hyperleptinemia (see reviews, Caro et al., 1996b; Spiegelman and Flier, 1996) . This has led to the concept of leptin resistance Spiegelman and Flier, 1996) . Figure 3 illustrates possible molecular scenarios that could lead to leptin resistance.
The most obvious target for a defect in leptin action is the leptin receptor. Defects in receptor expression or proximal signaling events in the brain could result in severe leptin resistance as observed in the db/db mouse. Additionally, downstream targets and effectors (many yet undefined) of leptin may be defective in certain forms of obesity.
Circulatory "defects" may also result in leptin resistance. The molecular form in which hormones circulate in blood can have a major impact on their biological activity. Many members of the cytokine family circulate bound to proteins in serum, and these binding proteins may play important roles in regulating hormone clearance rates, increasing or decreasing biological activity of the ligand, and(or) providing hormone responsiveness to unresponsive cells (Heaney and Golde, 1993; Bonner and Brody, 1995) . Houseknecht et al. (1996c) reported that leptin circulates specifically bound to at least three proteins in mouse serum and, in addition to Sinha et al. (1996b) and Diamond et al. (1997) , provided evidence of leptin binding proteins in humans. Figure 4 illustrates a ligand blot showing specific binding of [ 125 I]leptin to proteins in mouse and human serum. Sinha et al. (1996b) and Houseknecht et al. (1996c) found that in lean mice and humans, the majority of leptin circulates in the bound form, and that the proportion of free leptin is positively correlated with increasing obesity and body-mass index ( BMI) , indicating that leptin binding proteins are saturated with obesity. The precise identity of these proteins is currently unknown, as are the mechanism(s) that regulate their expression and their interaction with the leptin molecule. The leptin-binding protein interactions involve sulfhydryl bonds (Houseknecht et al., 1996c) . Many cytokines circulate bound to soluble forms of their receptors (Heaney and Golde, 1993; Bonner and Brody, 1995) . The leptin receptor is predicted to have multiple splice variants, including a proposed soluble receptor with predicted molecular weight of 85 kDa. In mice, we have reported specific leptin binding to a protein of approximately 85 kDa (Houseknecht et al., 1996c, see Figure 4 ). In humans, Caro's group (Sinha et al., 1996b) reported that only approximately 10% of leptin could be immunoprecipitated from serum using a leptin receptor antibody, suggesting that a soluble leptin receptor plays only a minor role in the human. It has been shown that leptin is transported into the brain by a saturable system (Banks et al., 1996; Schwartz et al., 1996b) , and that the efficiency of leptin transport is reduced in obese patients. It is possible that the bound form of leptin is the biologically active form, and(or) is necessary for transport across the blood-brain barrier. It is likely that the various serum leptin binding proteins affect leptin bioactivity and may be important in the development and(or) manifestation of leptin resistance.
A final possibility is that leptin resistance is not due to a pathological defect in leptin bioactivity, but may simply reflect the limitations of the leptin "system" to regulate food intake and body fat stores. Spiegelman and Flier (1996) proposed that the teleological role of leptin is not to avoid obesity, but to Figure 3 . Potential mechanisms of leptin resistance. Leptin resistance may be due to a defect in leptin binding protein abundance or profile, or in the transport of leptin across the blood-brain barrier. Leptin resistance may also be due to a leptin receptor signaling defect or a defect at the level of effector tissues. Finally, leptin resistance could be due to a synthesis/secretion defect occurring at the level of the adipocyte. NPY, neuropeptide Y; Leptin-BP, leptin binding proteins; ↑, increase, ↓, decrease. prevent death by starvation. Leptin could be a key regulator of survival during cycles of "feast and famine". This hypothesis is supported by the finding that exogenous leptin administration is able to at least partially overcome the neuroendocrine adaptations to starvation in mice (Ahima et al., 1996) . Further research is necessary to support/refute or refine the leptin resistance hypothesis.
Role of Leptin in the Regulation of Reproduction
The body of literature on the role of leptin in the control of reproduction is rapidly developing. At this time, the majority of information in this area has been obtained from research with human subjects and laboratory rodents. Information on domestic livestock is emerging but is limited due to the lack of sufficient quantities of recombinant leptin for whole-animal experiments and the lack of validated assays that can be used to monitor serum leptin secretion.
Nutrition-Reproduction Interactions
The importance of adequate nutritional intake in maintaining reproductive function is well-established (Asdell, 1949; Short and Bellows, 1971; Keane, 1975; Kirkwood and Aherne, 1985; Armstrong and Britt, 1987) . Inadequate nutrition delays or prevents the onset of puberty (Foster and Olster, 1985; Bronson, 1986; Aubert and Sizonenko, 1996) and interferes with normal cyclicity (Howland, 1971; Vigersky et al., 1977; Armstrong and Britt, 1987) . In males, undernutrition is accompanied by hypogonadism and infertility (Brown, 1994) . A consistent observation across species is that undernutrition results in decreased gonadotropin secretion (Kennedy and Mitra, 1963; Howland, 1971; Vigersky et al., 1977; Landefeld et al., 1989; Cameron et al., 1993) .
The mechanisms responsible for communicating nutritional status to the reproductive system have been sought for many years. A commonly held belief at one time was that the amount of body fat was a controlling factor in the onset of puberty and the maintenance of adult reproduction. More recent research has shown that metabolic and(or) nutritionally induced changes in reproductive function can occur without changes in body fat (Pettigrew and Tokach, 1991; Beltranena et al., 1993) . A variety of hormones may act as possible signals of nutritional status to the reproductive system (Pettigrew and Tokach, 1991) . Metabolites can exert potent effects on endocrine systems (Widmaier, 1992) and have been implicated in the control of gonadotropin secretion Pettigrew and Tokach, 1991) . To date, the mechanism of nutritional signaling to the reproductive system has not been clearly elucidated.
The relatively recent discovery of leptin (Zhang et al., 1994) has generated considerable excitement in the area of reproductive biology. Many believe that this hormone could be the long-sought indicator of nutritional status that allows reproductive processes to proceed. Leptin is produced in adipose tissue, which actively responds to nutritional and metabolic changes. The production of leptin increases with feeding and body fat content (Hamann and Matthaei, 1996) . Leptin receptors are found in the ventromedial and arcuate regions of the hypothalamus and are thus positioned anatomically in regions associated with the control of appetite and reproductive neuroendocrine function (Dyer et al., 1997) . Thus, leptin could provide an accurate, circulating signal of nutritional status.
Genetic and Nutritionally Induced Leptin Deficiency
Much of the evidence for the role of leptin as a reproductive hormone has been derived from ob/ob mice, which do not produce a functional leptin protein (Hamann and Matthaei, 1996) . An ob/ob female mouse is sterile and remains essentially in a constant prepubertal state. Ovarian and uterine weights, sex steroid concentrations, and pituitary gonadotropin secretion are depressed in these animals (Barash et al., 1996) . Administration of recombinant leptin to ob/ob female mice completely restores gonadotropin secretion, secondary sex organ weight and function, and fertility (Barash et al., 1996; Chehab et al., 1996) . Similar evidence has been obtained in ob/ob male mice. Male ob/ob mice demonstrate very low levels of fertility (Lane and Dickie, 1954) . These animals have low gonadotropin secretion and are hypogonadal (Swerdloff et al., 1978; Mounzih et al., 1997) . Seminiferous tubules contain few mature sperm, and Leydig cells are severely atrophied. As in female ob/ ob mice, leptin administration to the male mice restores fertility. Seminiferous tubules contain abundant sperm and Leydig cells show normal morphology following leptin treatment .
Thus, reproduction is restored by leptin administration in animals genetically lacking the expression of a functional leptin protein. Undernutrition results in a condition analogous to the ob/ob genotype, with inhibited leptin secretion and reproductive function. The effects of undernutrition on reproduction in nonobese animals also can be ameliorated by leptin treatment. The starvation-induced delay in ovulation in non-obese female mice is prevented by leptin treatment (Ahima et al., 1996) . Similarly, serum LH and testosterone levels are increased by leptin administration in fasted male mice (Ahima et al., 1996) . Restricting nutrition to 80% of ad libitum feed intake causes a >50% reduction in ovarian and uterine weights that is completely prevented by twice-daily injections of leptin (Cheung et al., 1997) .
Puberty
As stated above, undernutrition inhibits reproduction in mature animals and delays the onset of puberty as well. Feeding non-obese female rats at 80% of ad libitum intake was found to inhibit the onset of puberty, and no animals showed vaginal openings or estrus at 38 d of age (Cheung et al., 1997) . In contrast, normal onset of puberty occurred in rats treated with leptin, even though voluntary feed intake also was 80% that of control animals with ad libitum feed intake (Cheung et al., 1997) . Leptin also has been shown to advance puberty in non-obese mice with ad libitum feed intake. Leptin treatment that produced a reduction in food intake and growth by approximately 15% also advanced the onset of puberty by an average of 11 d (47.5 vs 36.5 d in saline vs leptin group; Chehab et al., 1997) . In a separate study, leptin treatment, which had no effect on food intake and growth, also advanced the onset of puberty in mice with ad libitum feed intake, but to a lesser degree .
The discovery that leptin treatment can advance reproductive maturation in undernourished and wellfed animals naturally raises the question as to whether leptin plays a role in the normal onset of puberty. The availability of immunoassays for leptin in rodents and humans has permitted evaluations of circulating leptin concentrations in the peripubertal period. Serum leptin concentrations increase during puberty onset in mice . Leptin secretion also transiently increases before puberty in boys . These observations suggest that a causal link between increasing leptin secretion and sexual maturation could exist.
The possibility also exists that increasing leptin sensitivity during early development could exert control over the timing of puberty. When adjusted for body fat, serum leptin concentrations were found to decrease during maturation in children (Hassink et al., 1996) . Because elevated serum leptin concentrations often accompany leptin resistance in obesity , the higher levels of leptin secretion in younger children (Hassink et al., 1996) may reflect a relative resistance to leptin. This resistance could serve to maintain high levels of food intake and growth, as well as preventing the premature onset of puberty. Consistent with this premise, a developmental decline in leptin gene expression with no concurrent change in body fat content has been observed in young pigs .
Leptin Effects on Reproduction: Mechanism(s) of Action
A logical first step in understanding the mechanisms by which leptin influences reproduction is to determine the location of functional receptors for this hormone. Leptin receptor mRNA has been localized in ventromedial and arcuate hypothalamic nuclei and in anterior pituitary tissue of sheep (Dyer et al., 1997) . In rats, leptin receptor mRNA can readily be detected in the ovary, testis, uterus, hypothalamus, and pituitary gland (Schwartz et al., 1996c; Zamorano et al., 1997) . Localization of the receptor in reproductive tissues likely occurs across species, because leptin receptor mRNA also is found in human ovaries and testes (Cioffi et al., 1996) . Leptin receptor gene expression also has been demonstrated in immortalized rat GnRH neurons and ovarian granulosa cells by RT-PCR analysis (Zamorano et al., 1997) .
Thus, leptin could act at multiple sites in the reproductive system. Leptin treatment enhances gonadotropin secretion (Barash et al., 1996) and ovarian side chain cleavage and 17a-hydroxylase mRNA levels (Zamorano et al., 1997) . Increased uterine weight in leptin-treated ob/ob mice seems to occur as a result of proliferative responses to increased ovarian estrogen production (Barash et al., 1996) . Similarly, trophic responses in seminal vesicles are likely a result of increased testosterone production (Barash et al., 1996) . Although the most accepted hypothesis is that the overall leptin-induced stimulation of reproductive function occurs secondarily to increased gonadotropin secretion, the possibility of direct effects cannot be discounted.
The evidence for neuroendocrine effects of leptin on GnRH release is convincing. Increased gonadotropin secretion consistently occurs as a result of leptin treatment in ob/ob mice and undernourished animals. Leptin treatment advances the onset of puberty, which is known to be controlled by hypothalamic release of GnRH. Hypothalamic GnRH release has long been recognized to be deficient in ob/ob mice (Swerdloff et al., 1978; Batt et al., 1982) . Leptin stimulates LH release in estrogen-primed ovariectomized rats, indicating stimulatory effects at the level of the anterior pituitary gland and(or) hypothalamus (Yu et al., 1997) . Leptin directly stimulates gonadotropin secretion from cultured rat, steer, and pig pituitary cells (Barb et al., 1997; Liou et al., 1997; Yu et al., 1997) . Cultured median eminence-arcuate explants from rats release GnRH in response to leptin (Yu et al., 1997) . The mechanism whereby leptin directly stimulates gonadotroph function is not known. There is reason to believe that the effects on hypothalamic GnRH release could be mediated by NPY.
Neuropeptide Y is a 36-amino acid neuropeptide found in areas of the hypothalamus involved in food intake and neuroendocrine control. Contrary to leptin, NPY is a potent stimulator of feed intake and inhibitor of gonadotropin secretion (Parrott et al., 1986; Pau et al., 1988; McDonald et al., 1989; Miner et al., 1989; McShane et al., 1992; Kalra and Kalra, 1996) . Undernutrition increases NPY gene expression in the arcuate (O'Shea and Gundlach, 1991; McShane et al., 1993; Adam et al., 1997) and elevates cerebrospinal fluid NPY concentrations (Kaye et al., 1990) . The increase in NPY production has been postulated to decrease the stimulatory input to downstream neural pathways that ultimately reach the GnRH neurons Schwartz et al., 1996c; Adam et al., 1997; Yu et al. 1997) . Leptin administration decreases NPY expression in the arcuate nucleus Schwartz et al., 1996c) , presumably removing the inhibition of GnRH release. These data have led to the speculation that receptors for leptin may exist on NPY neurons. In fact, leptin receptors have been localized recently on hypothalamic NPY neurons in mice (Mercer et al., 1996a) and sheep (Duane Keisler, University of Missouri, personal communication). Ob/ob mice that also are homozygous for a recessive mutant NPY allele have been generated (Erickson et al., 1996b) . These animals lack leptin and NPY and are less obese and more fertile than ob/ob mice with intact NPY production.
Implications for Reproduction
Even at this early stage of our understanding of leptin biology, there is considerable evidence that leptin regulates reproductive function in neuroendocrine, and perhaps reproductive, tissues. The potential applicability of this knowledge to improve the reproductive efficiency of livestock is open to speculation. However, removal of inhibitory input to the GnRH release mechanism certainly could facilitate reproductive function not only during the pubertal transition, but also during other periods of neuroendocrine quiescence, such as seasonal and postpartum anestrus. Decreasing postpartum leptin production in women could reflect a restoration of sensitivity to leptin conducive to resumption of reproductive capacity (Butte et al., 1997) . Obvious applications would also exist in stimulating reproduction during suboptimal nutrition and reduced body condition.
The Cytokinology of Leptin

Protein Structure
Structural characteristics linking the obese gene product, leptin, to the cytokine family are wellestablished. Results of several studies provide evidence that leptin is related to the family of helical cytokines, which includes IL-2 and growth hormone. Whereas there is no sequence similarity among the members of this family, all contain a distinctive threedimensional 4-a-helix bundle structure that has been indicated for leptin by threading analysis (Madej et al., 1995) , nuclear magnetic resonance techniques (Kline et al., 1997) , and the crystal structure of a mutant human leptin (Glu for Trp at position 100; Zhang et al., 1997) .
Leptin and Hematopoiesis
Normal cell turnover and the need to increase specific immune cell populations in response to pathogenic and nonpathogenic stimuli make necessary a means of replenishing and increasing blood and immune cell populations. These biological tasks are accomplished by the process called hematopoiesis. Through this process, the entire spectrum of erythroid, myeloid, and lymphoid cell populations are maintained throughout the life span of the animal (Shivdasani and Orkin, 1996; Leitman and Read, 1997) . A relatively small pool of pluripotent stem cells capable of self-renewal and differentiation give rise to all hematopoietic cell lineages. Differentiation of the stem cell results in populations of hematopoietic progenitor cells that show progressively greater commitment toward specific lineages and loss of ability for selfrenewal. These progenitor cells are capable of marked proliferation as an integrated response to numerous cytokines and growth factors.
The early indications that leptin might function in hematopoiesis arose from the cytokine characteristics of leptin and its receptor, the identification of leptin receptors in hematopoietic tissues, and from the adipocyte-specific expression of the obese gene given that adipocytes are the most abundant stromal cell type in adult human bone marrow (Gimble et al., 1996) . Thus, in addition to serving as a localized energy reservoir, the possibility that leptin produced within the marrow might regulate hematopoiesis was raised. Gainsford et al. (1996) documented the coexpression of OB-RL and OB-RS in numerous fetal and adult murine hematopoietic tissues. Furthermore, leptin enhanced cytokine production and parasite phagocytosis by murine peritoneal macrophages, and transfection studies indicated that the OB-RL receptor isoform stimulates proliferation of Ba/F3 cells and differentiation of M1 cells into macrophages. The OB-RS isoform, which lacks the box 1 and box 2 motifs of the hemopoietin receptor family, was nonfunctional in these studies. Ghilardi and Skoda (1997) obtained a similar proliferation response with the Ba/F3 cell line and linked it to activation of JAK2. Leptin has also been shown to stimulate fetal and adult erythroid and myeloid development (Mikhail et al., 1997) . Leptin increased macrophage number and granulocyte colony formation, and leptin and erythropoietin acted synergistically to stimulate erythropoiesis. Given these suggested roles of leptin in hematopoiesis, it is interesting to note that db/db mice, which express the truncated form of the leptin receptor, have reduced steady-state levels of some peripheral blood B and T cell populations and that marrow from this genotype has a deficit of lymphopoietic progenitors (Bennett et al., 1996) . Such was not the case in ob/ob mice. Thus, the possibility of an alternative ligand was suggested in the case of the ob/ob genotype. There is indeed considerable overlap among cytokines in their biological activities, and one might anticipate that other cytokines would overshadow the absence of leptin or its receptor (OB-RL) in these models. The basis for the apparent discrepancy between the ob/ob and db/ db genotypes remains to be determined.
Myriad cytokines and growth factors control the proliferation, survival, differentiation, and activity of immune cells (reviewed by Ellis et al., 1997) . Because a number of these regulatory agents are present in milk, interest in their possible roles in the development of neonatal and infant gastrointestinal immunity has been growing. In this regard, it is perhaps quite significant that leptin has been detected in human breast milk (Houseknecht et al., 1997a) , and levels in milk correlate with maternal plasma leptin concentrations and maternal adiposity (Houseknecht et al., 1997b) . Although temporal relationships between leptin concentrations and the development of neonatal and infant immune function have not been reported, leptin may indeed influence the onset of gut immunity or functional development. Further, leptin in milk may provide a link between maternal adiposity and neonatal metabolism and growth.
Leptin and the Acute Inflammatory Response
Anorexia and fever are common components of the physiological response to infection and inflammation that are mediated in part by the proinflammatory cytokine milieu within the brain (Johnson, 1997) . Thus, because leptin seems to be a powerful negative regulator of food intake and positive regulator of thermogenesis (discussed above), the question as to whether leptin contributes to the anorexia or the increased metabolic rate during infection has been raised. Grunfeld et al. (1996) and Sarraf et al. (1997) determined in rodents that administration of endotoxin and specific proinflammatory cytokines overrides the normal reduction in obese mRNA and blood leptin due to fasting and causes marked parallel increases in mRNA abundance and serum leptin in conjunction with reduced food intake. Ahima et al. (1996) proposed that neuroendocrine adaptations to food deprivation orchestrated by a reduction in circulating leptin may be the primary biological role of this protein. It is therefore necessary to reconcile potential consequences of a lack of such adaptations in immunologically challenged animals in which leptin concentrations are increased despite food deprivation. However, it should also be noted that a response similar to that described for rodents may not occur in pigs. Leptin mRNA abundance is not influenced, at least acutely ( 4 h), by endotoxin challenge despite clear clinical indications of a strong acute inflammatory response to the endotoxin in young pigs (M. E. Spurlock, personal communication).
All things considered, it may well be that an increase in the circulating leptin concentration in response to infection or inflammation is multipurposed, encompassing regulation of food intake, metabolic rate, macrophage function, and induction of immune cell proliferation or differentiation. It will be interesting to determine whether the immunological responses to infection influenced by leptin are different in db/db or ob/ob mice.
Potential Medical Applications for Leptin
Pharmaceutical companies have invested heavily in leptin since 1995. In June 1997, Amgen, a licensee of the Freidman and Rockefeller University leptin patents, announced the successful completion of their Phase 1 regulatory trials with a leptin injectable product. They will be moving on to "... Phase 2 testing of leptin both for weight reduction in obese patients and for those obese patients with the form of diabetes known as non-insulin dependent diabetes mellitus or NIDDM" (Business Wire, June 17, 1997). They reported that there is a dose range in which leptin seemed to be safe for use in humans, but there were injection site reactions, especially with multiple daily injections at the higher doses tested. It is likely that other product concepts will soon be tested in clinical trials to take advantage of the highly desirable effects of leptin on obesity. More complex leptin formulations or other molecules that act on some component of the leptin axis are likely to be in the pipeline soon, and these would be expected to be easier for patients to use than daily injections. The commercial opportunities are some of the largest in the health care arena and thus have attracted huge investments that have driven the tremendous growth in the understanding of this exciting new component of energy balance regulation and obesity.
Applications for Animal Agriculture
Although obesity per se is not a major problem for animal agriculture, improvement of productive efficiency, carcass composition, and animal health and well-being are important goals. The published literature concerning leptin biology in livestock species is small; however, the porcine leptin gene has been cloned (Bidwell et al., 1997) and multiple abstracts and papers are in press. If leptin biology is similar for livestock species and human and rodent species, it is clear that leptin has myriad effects on tissues and endocrine systems that ultimately lead to the coordination of whole-body energy metabolism. Thus, leptin is a homeorhetic hormone that may have a major impact on the performance and well-being of livestock species. Leptin may be classified as a "metabolism modifier"; thus, we can predict that the manipulation of leptin expression and(or) action will be of interest to scientists and pharmaceutical companies wishing to improve productive performance of animals. Furthermore, if leptin is involved in animal responses to disease or stress, the manipulation of leptin action may become an important therapy in the treatment of animal disease.
Direct leptin treatment will not be feasible in livestock production unless affordable, potent analogs or delivery systems are developed. Until then, successful enhancement of reproductive function or manipulation of nutrient partitioning are more likely to be achieved through regulation of leptin production or sensitivity to leptin through nutritional or metabolic manipulation. Genetic selection also could be used to this end. Expressed (Matteri et al., 1998) and intronic (Sasaki et al., 1996) polymorphisms in the leptin gene that may be useful in RFLP-based selection have been discovered.
Implications
Meeting the challenge of optimizing productive efficiency, product quality, and animal health and well-being requires a thorough understanding of the mechanisms that regulate and coordinate feed intake and energy metabolism in food animals. Data, largely from rodent and human studies, indicate that leptin may play a vital role in coordinating feed intake, energy expenditure, and tissue nutrient utilization under many physiological and pathological conditions. Extensive studies are needed to determine the importance of leptin in the physiology and productivity of food animals.
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